AstraZeneca PLC · Overview · TradingHolo

AstraZeneca PLC · Overview · TradingHolo

1D

−0.8%

1M

+1.5%

3M

−2.1%

6M

−17.5%

1Y

−2.2%

Why it's moving today

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

BusinessWire · Mon 19 Oct

✦ This week in three lines

No written digest yet for AZN. The figures on this page are the source when one is written.

Financials

USD billions · annual5Y CAGR +17.2%

Valuation

P/E vs sector25.0× vs −1.7×

Price / Book vs sector5.3× vs 2.0×

Price / Sales vs sector4.4× vs 3.9×

Price / Free cash flow vs sector29.6× vs −1.6×

cheap for itself (19.6×)expensive for itself (78.5×)

Forecasts

25 buy7 hold0 sell32 analysts

Average target$0.0000 −100.0%

Analysts0

EPS surprises, last 86 beats

Dividends

Yield1.9%

Annual payout$4.28

Payout ratio48.5%

Next ex-date—

Years of growth2

Latest news

All AZN news →

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

BusinessWire · 10 h ago

AstraZeneca inks AI drug discovery deal worth up to $1.5B with insitro

Seeking Alpha · 4 d ago

Hospital group files lawsuit to stop 340B rebate pilot again

Seeking Alpha · 9 d ago